Gennex Laboratories passes all resolutions at 41st AGM
- Gennex Laboratories held its 41st electronic AGM on September 30, 2026, with all four resolutions passed by requisite majority
- Total shareholders on record as on the cut-off date of September 23, 2026 stood at 81,565; 120 members voted via remote e-voting
- Resolution 1 (adoption of financial statements for FY ended March 31, 2026) passed with 99.9696% votes in favour
- Resolution 3 (appointment of Dipankar Dasgupta as Independent Non-Executive Director) passed as a Special Resolution with 99.8706% votes in favour
- Resolution 4 (ratification of remuneration of M/s. Sai Krishna & Associates for FY ending March 31, 2027) passed with 99.8730% votes in favour
*this image is generated using AI for illustrative purposes only.
Gennex Laboratories held its 41st electronic Annual General Meeting on September 30, 2026, at 12:30 pm through Video Conferencing/Other Audio Visual Means. All four resolutions set out in the AGM notice dated September 4, 2026 were passed with requisite majority.
Meeting participation and voting overview
The cut-off date for determining voting entitlements was September 23, 2026, on which date the total number of shareholders on record stood at 81,565. Remote e-voting was conducted via the National Securities Depository Limited platform and remained open from September 27, 2026 (9:00 am) to September 29, 2026 (5:00 pm). A total of 120 members cast their votes through remote e-voting; no member voted through e-voting at the AGM.
Shareholder attendance at the meeting through VC/OAVM is summarised below:
| Category | Shareholders present via VC/OAVM | Shareholders voted via e-voting |
|---|---|---|
| Promoter and Promoter Group | 5 | 6 |
| Public | 42 | 114 |
Resolution-wise voting results
The following table presents the consolidated voting outcome for all four resolutions across a total of 242,947,674 shares:
| Resolution | Description | Type | Total votes polled | Votes in favour | % in favour | Votes against | % against |
|---|---|---|---|---|---|---|---|
| 1 | Adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026 | Ordinary | 29,031,737 | 29,022,915 | 99.9696 | 8,822 | 0.0304 |
| 2 | Re-appointment of Dr. Avasarala Ranga Rao Pantulu (DIN: 09003006) as director retiring by rotation | Ordinary | 29,031,737 | 28,994,858 | 99.8730 | 36,879 | 0.1270 |
| 3 | Appointment of Mr. Dipankar Dasgupta (DIN: 05312364) as Independent Non-Executive Director | Special | 29,031,737 | 28,994,158 | 99.8706 | 37,579 | 0.1294 |
| 4 | Ratification of remuneration of M/s. Sai Krishna & Associates, Cost Accountants (Regn No. 001742) for the financial year ending March 31, 2027 | Ordinary | 29,031,737 | 28,994,858 | 99.8730 | 36,879 | 0.1270 |
Total votes polled across all resolutions represented 11.9498% of outstanding shares. No invalid votes were recorded for any resolution.
Promoter and public institutional voting breakdown
The Promoter and Promoter Group held 57,405,624 shares and cast 28,592,024 votes via remote e-voting for each resolution, representing 49.8070% of their shareholding, with 100.0000% of those votes cast in favour across all four resolutions. Public Institutions held zero shares and recorded no votes. Public Non-Institutions held 185,542,050 shares and polled 439,713 votes for each resolution, representing 0.2370% of their shareholding.
Scrutinizer's findings
The voting process was overseen by Sweety Kapoor, Practising Company Secretary (Membership No. FCS 6410, CP No. 5738), appointed as Scrutinizer. Results were unblocked on September 30, 2026, at approximately 1:30 pm in the presence of two witnesses. The Scrutinizer confirmed that all resolutions were passed with requisite majority and that electronic voting data will remain in custody until the Chairman approves and signs the minutes, after which it will be handed over to the Company Secretary.
Historical Stock Returns for Gennex Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.60% | -4.17% | -23.39% | +38.71% | -11.54% | +49.85% |
How will the appointment of Mr. Dipankar Dasgupta as an Independent Non-Executive Director influence Gennex Laboratories' strategic direction and governance standards in the upcoming fiscal year?
What specific operational or financial challenges might the company address in FY2027 following the ratification of the new cost auditor's remuneration?
Given the low public institutional participation, what measures might Gennex Laboratories implement to enhance retail shareholder engagement and voting turnout in future AGMs?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
